novofem filmuhúðuð tafla
novo nordisk a/s* - estradiol; norethisteronum acetat - filmuhúðuð tafla
trisekvens filmuhúðuð tafla
novo nordisk a/s* - estradiol; norethisteronum acetat - filmuhúðuð tafla
activelle filmuhúðuð tafla 1mg/0,5 mg
novo nordisk a/s* - norethisteronum acetat; estradiolum inn - filmuhúðuð tafla - 1mg/0,5 mg
ovestin leggangakrem 1 mg/g
aspen pharma trading limited - estriolum inn - leggangakrem - 1 mg/g
ovestin leggangastíll 0,5 mg
aspen pharma trading limited - estriolum inn - leggangastíll - 0,5 mg
estring leggangainnlegg 7,5 míkróg/24 klst.
pfizer aps - estradiol - leggangainnlegg - 7,5 míkróg/24 klst.
femanor tafla 2 mg+1 mg
viatris aps - norethisteronum acetat; estradiol - tafla - 2 mg+1 mg
cyproteroneacetat/etinylestradiol alvogen (cypretyl) húðuð tafla 2/0,035 mg
alvogen ehf. - ethinylestradiolum inn; cyproteronum acetat - húðuð tafla - 2/0,035 mg
mirena (levonova) leginnlegg 20 míkróg/24 klst.
bayer ab* - levonorgestrelum inn - leginnlegg - 20 míkróg/24 klst.
orserdu
stemline therapeutics b.v. - elacestrant - brjóstakrabbamein - innkirtla meðferð - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.